MiNK Therapeutics (INKT) Change in Account Payables (2020 - 2026)

MiNK Therapeutics has reported Change in Account Payables for 7 years, with the latest figure at -$32414.0 in Q1 2026.

• Quarterly Change in Account Payables rose 52.75% year-over-year to -$32414.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $725902.0 (up 187.82% YoY) and the FY2025 annual result came in at $689710.0, up 158.33% from the prior year.
• Change in Account Payables climbed to -$32414.0 in Q1 2026 per INKT's latest filing, from -$269595.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $968065.0 in Q2 2022 and troughed at -$1.1 million in Q2 2023.
• A 5-year average of $12829.1 and a median of -$32414.0 in 2026 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2024 and 2025: Change in Account Payables tumbled 375.75% in 2024, then soared 326.87% in 2025.
• Over 5 years, Change in Account Payables stood at $570307.0 in 2022, then plunged by 165.46% to -$373341.0 in 2023, then surged by 200.22% to $374149.0 in 2024, then tumbled by 172.06% to -$269595.0 in 2025, then surged by 87.98% to -$32414.0 in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$32414.0, -$269595.0, and $381852.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.